Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Premier, Inc. (NASDAQ:PINC)
- Dividend Yield: 3.75%
- Baird analyst Eric Coldwell maintained a Neutral rating and raised the price target from $19 to $20 on Nov. 6, 2024. This analyst has an accuracy rate of 60%.
- Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 69%.
- Recent News: On Feb. 4, Premier posted downbeat quarterly results.
- Benzinga Pro's real-time newsfeed alerted to latest PINC news.
Bristol-Myers Squibb Company (NYSE:BMY)
- Dividend Yield: 4.14%
- Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $60 to $65 on Jan. 28. This analyst has an accuracy rate of 71%.
- B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $63 on Dec. 10, 2024. This analyst has an accuracy rate of 62%.
- Recent News: On Jan. 31, Bristol Myers Squibb received positive CHMP opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma.
- Benzinga Pro's real-time newsfeed alerted to latest BMY news
CVS Health Corporation (NYSE:CVS)
- Dividend Yield: 4.75%
- Truist Securities analyst David Macdonald maintained a Buy rating and cut the price target from $67 to $60 on Jan. 6. This analyst has an accuracy rate of 68%.
- Deutsche Bank analyst George Hill upgraded the stock from Hold to Buy with a price target of $66 on Dec. 3, 2024. This analyst has an accuracy rate of 60%.
- Recent News: CVS Health will hold a conference call on Wednesday, Feb. 12, to discuss fourth quarter and full year 2024 financial results.
- Benzinga Pro’s real-time newsfeed alerted to latest CVS news
Read More:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: dividend yield Expert IdeasNews Price Target Pre-Market Outlook Markets Analyst Ratings Trading Ideas
